Instituto do Câncer de São Paulo - ICESP, São Paulo, SP, Brasil.
Divisão de Urologia, Faculdade de Medicina, Universidade de São Paulo, SP, Brasil.
Int Braz J Urol. 2021 Mar-Apr;47(2):378-385. doi: 10.1590/S1677-5538.IBJU.2020.0479.
The rapid spread of coronavirus disease 2019 (COVID-19) has dramatic effects on individuals and health care systems. In our institute, a tertiary oncologic public hospital with high surgical volume, we prioritize maintaining cancer treatment as well as possible. The aim of this study is to evaluate if uro-oncological surgeries at pandemic are safe.
We evaluated patients who underwent uro-oncological procedures. Epidemiological data, information on COVID-19 infection related to surgery and clinical characteristics of non-survival operative patients with COVID-19 infections were analyzed.
From 213 patients analyzed, Covid-19 symptoms were noticed in 8 patients at preoperative process or at hospital admission postponing operation; 161 patients were submitted to elective surgery and 44 to emergency surgery. From patients submitted to elective surgeries, we had 1 patient with laboratory confirmation of COVID-19 (0,6%), with mild symptoms and quick discharge. From the urgencies group, we had 6(13%)patients tested positive; 5 were taken to ICU with 4 deaths.
Elective uro-oncological procedures at the COVID-19 epidemic period in a COVID-19-free Institute are safe, and patients who need urgent procedures, with a long period of hospitalization, need special care to avoid COVID-19 infection and its outcomes.
2019 年冠状病毒病(COVID-19)的迅速传播对个人和医疗保健系统产生了巨大影响。在我们的研究所,一家拥有大量外科手术量的三级肿瘤公立教学医院,我们优先尽可能地维持癌症治疗。本研究旨在评估大流行期间的泌尿肿瘤外科手术是否安全。
我们评估了接受泌尿肿瘤手术的患者。分析了流行病学数据、与手术相关的 COVID-19 感染信息以及 COVID-19 感染非存活手术患者的临床特征。
在分析的 213 名患者中,有 8 名患者在术前过程或住院期间出现了新冠病毒症状,推迟了手术;161 名患者接受了择期手术,44 名患者接受了紧急手术。在接受择期手术的患者中,我们有 1 名患者的 COVID-19 实验室检测呈阳性(0.6%),症状较轻,很快出院。在紧急手术组中,我们有 6 名(13%)患者检测呈阳性;其中 5 名患者转入 ICU,4 人死亡。
在无 COVID-19 的研究所,COVID-19 流行期间进行的择期泌尿肿瘤手术是安全的,而需要紧急手术、住院时间较长的患者需要特别护理,以避免 COVID-19 感染及其后果。